Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-03T14:02:09.616Z Has data issue: false hasContentIssue false
  • English
  • Français

Serum prolactin levels and sexual dysfunctions in antipsychotic medication, such as risperidone: a review

Published online by Cambridge University Press:  18 September 2015

H. Knegtering ,
P.A. Lambers ,
G. Prakken  and
C. ten Brink
H. Knegtering*
Affiliation:
Psychiater, Academisch Ziekenhuis Groningen
P.A. Lambers
Affiliation:
Psychiater i.o., Academisch Ziekenhuis Groningen
G. Prakken
Affiliation:
Arts-assistent Algemeen Psychiatrisch Ziekenhuis Drenthe, Assen
C. ten Brink
Affiliation:
Psychiater i.o., Academisch Ziekenhuis Groningen
*
Psychiatrische Universiteitskliniek, Academisch Ziekenhuis Groningen, Postbus 30.001 9700 RB Groningen
Get access Rights & Permissions [Opens in a new window]

Summary

Classical antipsychotic drugs increase the level of serum prolactin. The atypical antipsychotic clozapine barely increases prolactin levels. An open naturalistic study in the University Hospital of Groningen suggests that treatment with risperidone in comparison to classical antipsychotics seems to increase the risk of erectile and ejaculatory disorders in male patients and to menstrual disturbances in female patients. In the literature reviewed, risperidone is associated with higher prolactin levels in comparison to classical antipsychotics. It is still unclear which mechanism is responsible for the increase of serum prolactin levels and sexual dysfunctions in patients using risperidone. Dopaminergic and serotonergic receptor blockade seems to play an important role. Other mechanisms are discussed.

Keywords

Atypical antipsychoticsmenstrual disturbancesprolactinrisperidonesexual dysfunctiontypical antipsychotics
Type
Articles
Information
Acta Neuropsychiatrica , Volume 12 , Issue 1 , March 2000 , pp. 19 - 26
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

1.Knegtering, H, Boks, MPM, Brink, C ten. Sexual dysfunction and serum prolactin levels in patients using classical antipsychotics or risperidone. Schizophr Res (suppl), 1998:186.CrossRefGoogle Scholar
2.Knegtering, H, Blijd, C, Boks, M. Sexual functions and prolactin levels in patients using classical antipsychotics, risperidone or olanzapin. Schizophr Res, (suppl) in press.Google Scholar
3.denBussche, G van Bussche, G van, Heykants, J, Coster, R de. Pharmacokinetic profile and neuroendocrine effects of the new antipsychotic risperidone. Psychopharmacology 1988;96(suppl):334.Google Scholar
4.Mesotten, F, Suy, E, Pietquin, M, et al.Therapeutic effect and safety of increasing doses of risperidone (R64766) in psychotic patients. Psychopharmacology 1989;99:445–449.CrossRefGoogle ScholarPubMed
5.Bersani, G, Bressa, GM, Meco, G, et al.Combined sertonin-5-HT2 and dopamin-D2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrin respons in a preliminary study with risperidone (R64766). Hum Pharmacol 1990;5:225–231.Google Scholar
6.Huang, M-L, Van Peer, A, Woestenborghs, R, et al.Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin respons in healthy subjects. Clin Pharmacol Ther 1993;54:257–268.CrossRefGoogle Scholar
7.Dickson, RA, Dalby, JT, Williams, R, Edwards, AL. Risperidone induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry 1995;112:1102.Google Scholar
8.Marder, SR, Melbach RG Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825–835.Google Scholar
9.Peuskens, J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-centre, double-blind parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712–726.CrossRefGoogle ScholarPubMed
10.Claus, A, Bollen, J, De Cuyper, H, et al.Risperidone versus haloperidol in the treatment of chronic inpatients: a multicentre, double-blind comparative study. Acta Psychiatr Scand 1992;85:295–305.CrossRefGoogle ScholarPubMed
11.Knegtering, H, Boks, M, Brink, C ten. Sex differences in sexual dysfunctions and serum prolactin levels in patients using classical antipsychotics or risperidone. Poster, Voorjaarscongres Nederlandse Vereniging voor Psychiatrie 1998.Google Scholar
12.Schwartz, MF, Bauman, JE, Masters, WH. Hyperprolactinemia and sexual disorders in men. Biol Psychiatry 1982;17:861–876.Google ScholarPubMed
13.Pollack, MH, Reiter, S, Hammerness, P. Genitourinary and sexual adverse effects of psychotropic medication. Int J Psychol Med 1992;22:305–327.CrossRefGoogle ScholarPubMed
14.Caranai, C, Granata, AR, Fustini, MF, Marrara, P. Prolactin and testosterone: their role in male sexual function. Int J Androl 1996;19:48–54.CrossRefGoogle Scholar
15.Hermanns, U, Hafez, ESE. Prolactin and male reproduction. Arch Androl 1981;6:95–125.CrossRefGoogle ScholarPubMed
16.Tuomisto, T. Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 1985;37:249–332.Google ScholarPubMed
17.Green, AJ, Brown, WA. Prolactin and neuroleptic drugs. Neurol Clin 1988;6:213–223.CrossRefGoogle ScholarPubMed
18.Gitlin, MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology and treatment approaches. J Clin Psychiatry 1994;55:406–413.Google ScholarPubMed
19.Sailer, CF, Czupryna, MJ, Salama, AI. 5-HT2 receptorblockade by ICI 169,39 and other 5-HT2 antagonists modulates the effects of D2 Dopamine receptor blockade. Pharmacol Ther 1990;253:1162–1170.Google Scholar
20.Coccaro, EF, Kavoussi, RJ, Oakes, M, Cooper, TB, Hauger, R. 5-HT2a/2c receptor blockade by amersergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects. Psychopharmacol 1996;126:24–30.CrossRefGoogle Scholar
21.Mulronyey, SE, Skudlarek, C, Shemer, A, Lumpkin, MD, Kellar, KJ. Tandospirone stimulates prolactin secretion in the rat by an action at serotonin-1A receptors. J Pharmacol Exp Ther 1994;268:862–867.Google Scholar
22.Kar, LD van de, Rittenhouse, PA, Li, Q, Levy, AD. Serotonergic regulation of renin and prolactin secretion. Beh Brain Res 1996; 73:203–208.Google ScholarPubMed
23.Thorner, M, Vance, ML, Horvath, E, Kovacs, K. The anterior pituitary. In: Wilson, JD, Foster, DW, eds. Williams Textbook of Endocrinology. Philadelphia, WBSaunders 1992, pp 193–228.Google Scholar
24.Ulrich, U, Norwara, I, Rossmanith, WG. Serotonergic control of gonadothrophin and prolactin secretion in women. Clin Endocrinol 1994;41:779–788.CrossRefGoogle Scholar
25.Reichlin, S. The anterior pituitary. In: Wilson, JD, Foster, DW, eds. Williams Textbook of Endocrinology. Philadelphia, WBSaunders, 1992, pp 193–228.Google Scholar
26.Gitlin, MJ. Psychotropic medications and their effects on sexual function: Diagnosis, biology and treatment approaches. J Clin Psychiatry 1994;55:406–413.Google ScholarPubMed
27.Patel, AG, Mukherji, K, Lee, A. Priatism associated with psychotropic drugs. Br J Hosp Med 1996;55:315–319.Google ScholarPubMed
28.Lane, RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction: incidence, possible aetiology and implications for management. J Psychopharmacol 1997;11:72–82.CrossRefGoogle ScholarPubMed
29.Wilson, CA. Pharmacological targets for the control of male and female sexual behaviour. In: Riley, AJ, Peet, M, Wilson, C, eds. Sexual Pharmacology. Oxford, Clarendon Press 1993, pp 1–58.Google Scholar
30.Baldwin, DS, Thomas, SC, Birtwistle, J. Effects of antidepressant drugs on sexual function. Int J Psychiatry Clin Prac 1997;1:47–58.CrossRefGoogle ScholarPubMed
31.Grant, S, Fitton, A. Risperidone, a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994;48:253–272.CrossRefGoogle ScholarPubMed
32.Leysen, JE, Janssen, PMF, Gommeren, W, Wynants, J, Pauwels, PJ, Janssen, PAI. In vitro and in vivo receptor binding and effects on monoamin turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mod Pharmacol 1992;41:494–508.Google ScholarPubMed
33.Leysen, JE, Gommeren, W, Eens, A, et al.Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661–670.Google ScholarPubMed
34.Leysen, JE, Janssen, PMF, Megens, AAHP, Schotte, A. Risperidone: a novel antipsychotic with balanced serotonin dopamine antagonism, receptor occupancy profile and pharmacologic activity. J Clin Psychiatry 1994;55(suppl):5–12.Google ScholarPubMed
35.Nyberg, S, Farde, L, Eriksson, L, et al.5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology 1993;110:265–272.CrossRefGoogle Scholar
36.Bursatto, GF, Pilowsky, LS. Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone. Br J Psychiatry 1993;163:833–840.Google Scholar
37.Bursatto, GF, Pilowsky, LS, Costa, DC, Ell, PJ, Verhoeff, NPLG, Kerwin, RW. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride - an 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacology 1995;117:55–61.CrossRefGoogle Scholar
38.Farde, L, Nyberg, S, Oxenstierna, G, Nakashima, Y, Halldin, C, Ericsson, B. Positron emission tomography studies on D2 and 5HT-2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychophamacol 1995;15(suppl):19–23.CrossRefGoogle Scholar
39.Farde, L. Nordstrom, A-L, Wiesel, F-A, Pauli, S, Halldin, C, Sedvall, G. Positron emission tomography analysis of centrel D1 and D2 dopamine occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992;49:538–544.CrossRefGoogle Scholar
40.Boer, JA den, Louwerens, JW, Ellenbroek, BA. Nieuwe ontwikkelingen op het gebied van atypische antipsychotica. In: Boer, JA den, Bosch, RJ van den, eds. Leerboek Schizofrenie. Utrecht, De Tijd-stroom, 1996:302–303.Google Scholar
41.Riley, AJ, Riley, EJ. Evaluation of drug effects on human sexual dysfunction. In: Riley, AJ, Peet, M, Wilson, C, eds. Sexual Pharmacology. Oxford, Clarendon Press 1993: pp 114–129.CrossRefGoogle Scholar
42.Shen, WW, Sata, LS. Inhibited female orgasm resulting from psychotropic drugs: a five year, updated clinical review. J Reprod Med 1990;35:83–84.Google ScholarPubMed
43.Aizenberg, D, Zemishlany, Z, Dorfman Etrg, P, Weizman, A. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 1995;56:137–141.Google ScholarPubMed